Article information
Abstract
Background
This study evaluated the role of HA as a marker of liver fibrosis in patients with hepatitis C on haemodialysis.
MethodsThis is a cross-sectional study in which 52 patients were divided into two groups: Group 1: patients with hepatitis C and end-stage renal disease (ESRD) undergoing haemodialysis (n = 23); and Group 2: patients with hepatitis C without ESRD (n = 29). Plasma levels of HA were associated with histological data of the samples obtained by liver biopsy and classified by METAVIR group scoring system.
ResultsHigher plasma levels were significantly correlated to significant liver fibrosis (METAVIR ≥ F2). In Group 1, the HA cutoff to discriminate significant fibrosis was 984.8 ng/mL, with accuracy, sensitivity and specificity of 80.8%, 83.0%, and 70.0%, respectively. In Group 2, the HA cutoff was 222.3 ng/mL, with accuracy, sensitivity and specificity of 74.5%, 70.0%, and 94.0%, respectively.
ConclusionHA was an accurate noninvasive marker in predicting significant fibrosis in patients with hepatitis C on haemodialysis.
Keywords:
liver fibrosis
hyaluronic acid
end-stage renal disease
haemodialysis
hepatitis C
Full text is only aviable in PDF
References
[1.]
F. Fabrizi, F.F. Poordad, P. Martin.
Hepatitis C infection and the patient with end-stage renal disease.
Hepatology, 36 (2002), pp. 3-10
[2.]
M.A. Carneiro, R.M. Martins, A.S. Teles, et al.
Hepatitis C prevalence and risk factors in hemodialysis patients in Brazil: a survey by polimerase chain reaction and serological.
Mem Inst Oswaldo Cruz, 96 (2001), pp. 765-769
[3.]
G.O. Santana, H.P. Cotrim, E. Mota, et al.
Anti-HCV in patients undergoing hemodialysis in Salvador, BA, Brazil.
Arq Gastroenterol, 38 (2001), pp. 24-31
[4.]
M.T.G. Medeiros, J.M. Coelho-Filho.
Prevalence and associated factors to hepatitis C in hemodialisys patients in Brazil.
Rev Saúde Pública, 38 (2004), pp. 187-193
[5.]
F. Fabrizi, P. Martin, G. Lunghi, C. Ponticelli.
Nosocomial transmission of hepatitis C virus infection in hemodialysis patients: Clinical perspectives.
Int J Artif Organs, 23 (2000), pp. 805-816
[6.]
M. Jadoul.
Epidemiology and mechanisms of transmission of the hepatitis C virus in hemodialysis.
Nephrol Dial Trans, 15 (2000), pp. S39-S41
[7.]
E. Nakayama, T. Akiba, F. Marumo, et al.
Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy.
J Am Soc Nephrol, 11 (2000), pp. 1896-1902
[8.]
O. Yokosuka, K. Okuda.
Natural history of chronic hepatitis C in patients on hemodialysis: case-control study with 4-23 years of follow-up.
World J Gastroenterol, 10 (2004), pp. 2209-2212
[9.]
F. Gonzáles-Roncero, M.A. Gentil, M.A. Valdivia.
Outcome of kidney transplant in chronic hepatitis C virus patients: effect of pretransplantation interferon-alpha 2b monotherapy.
Transplant Proceed, 35 (2003), pp. 1745-1747
[10.]
R.J. Fontana, A.S.F. Lok.
Noninvasive monitoring of patients with chronic hepatitis C.
Hepatology, 36 (2002), pp. 557-563
[11.]
S.J. Cotler, G. Diaz, S. Gundlapalli, et al.
Characteristics of hepatitis C in renal transplantation candidates.
J Clin Gastroenterol, 35 (2002), pp. 191-195
[12.]
W. Albuquerque, V. Arantes, K. de Paula Farah, et al.
Acute pancreatitis and acute cholecystitis caused by hemobilia after percutaneous ultrasound-guided liver biopsy.
Endoscopy, 37 (2005), pp. 1159-1160
[13.]
K. de Paula Farah, R.A. Carmo, C.M. de Figueiredo Antunes, J.C. Serufo, et al.
Hepatitis C, HCV genotypes and hepatic siderosis in patients with chronic renal failure on haemodialysis in Brazil.
Nephrol Dial Transplant, (2007), pp. 2027-2031
[14.]
J. Guechot, A. Laudat, A. Loria, et al.
Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis.
Clin Chem, 42 (1996), pp. 558-563
[15.]
V.S. Wong, V. Hughes, A. Trull.
Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection.
J Viral Hepatitis, 5 (1998), pp. 187-192
[16.]
J.N. Plevris, G.H. Haydon, K.J. Simpson.
Serum hyaluronan: a non-invasive test for diagnosing liver cirrhosis.
Eur J Gastroenterol Hepatol, 12 (2000), pp. 1121-1127
[17.]
P. Halfon, M. Bourliere, G. Penaranda, et al.
Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus.
Comp Hepatol, 11 (2005), pp. 4-6
[18.]
C.T. Wai, J.K. Greensson, R.J. Fontana, et al.
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.
Hepatology, 38 (2003), pp. 518-526
[19.]
F. Imbert-Bismut, V. Ratziu, L. Pieroni, et al.
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.
Lancet, 357 (2001), pp. 1069-1075
[20.]
N.V. Chrysanthos, G.V. Papatheodoridis, S. Savvas, et al.
Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis.
Eur J Gastroenterol Hepatol, 18 (2006), pp. 389-396
[21.]
L.L. Schiavon, R.J. Carvalho Filho, J.L. Narcizo Schiavon, et al.
Simple blood test as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection.
Hepatology, 46 (2007), pp. 307-314
[22.]
L.L. Schiavon, J.L. Narciso-Schiavon, R.J. Carvalho Filho, et al.
Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection.
J Viral Hepat, 15 (2008), pp. 666-674
[23.]
P. Bedossa, T. Poynard.
An algorithm for the grading of activity in chronic hepatits C.
Hepatology, 24 (1996), pp. 289-293
[24.]
J.H. Turney, A.M. Davison, M.A. Forbes, et al.
Hyaluronic acid in end-stage renal failure treated by hemodialysis: Clinical correlates and implications.
Nephrol Dial Transplant, 6 (1991), pp. 566-570
[25.]
N. Furusyo, J. Nayashi, Y. Kanamoto-Tanaka, et al.
Liver damage in hemodialysis patients with hepatitis C virus viremia: A prospective 10-year study.
Dig Dis Sci, 45 (2000), pp. 2221-2228
[26.]
M. de Medina, M. Hill, H.O. Sullivan, B. Leclerq, et al.
Detection of anti-hepatitis C virus antibodies in patients undergoing dialysis utilizing a hepatitis C virus 3.0 assay: correlation with hepatitis C virus RNA.
J Lab Clin Med, 132 (1998), pp. 73-75
[27.]
G.L. Wong.
Paracrine interactions in bone-secreted products of osteoblasts permit osteoclasts to respond to parathyroid hormone.
J Biol Chem, 259 (1984), pp. 4019-4022
[28.]
R.J. Midura, X. Su, J.A. Morcuende, et al.
Parathyroid hormone rapidly stimulates hyaluronan synthesis by periosteal osteoblasts in the tibial diaphysis of the growing rat.
J Biol Chem, 278 (2003), pp. 51462-51468
[29.]
D. Hughes, A. Dai, J.C. Tiffee, H.H. Li, et al.
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta.
Nat Med, 2 (1996), pp. 1132-1136
[30.]
T. Suda, N. Udagawa, I. Nakamura, et al.
Modulation of osteoclast differentiation by local factors.
Bone, 28 (1995), pp. 87-91
[31.]
C. Trocme, V. Leroy, N. Sturn, et al.
Longitudinal evaluation of a fibrosis index combining MMP-1 and P III NP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
J Viral Hepat, 13 (2006), pp. 643-651
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved
